Navigation Links
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Date:8/19/2007

HREF="http://www.vionpharm.com" target="_new">http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Anthropology professors blog raises public interest
4. Interest drives investment of instructional technology
5. High interest forces delay in food safety symposium
6. A Vote Against Free Trade is a Vote Against Wisconsins Long-Term Interests
7. SecurePipe appoints two senior execs
8. Third Wave announces two senior management appointments
9. Senior Wisconsin stem-cell researcher leaves for Connecticut
10. Sonic Foundry names new senior vice president
11. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... The Conferee Networking committee is pleased ... Networking. These two-hour sessions provide a unique networking opportunity ... problems, discuss new techniques, or brainstorm new ideas in ... topic for consideration is August 31, 2014, and instructions ... Networking committee will review the topics, and status notifications ...
(Date:7/25/2014)... Lawrence Livermore scientists Charles Westbrook and William Pitz ... The World's Most Influential Scientific Minds ." , Westbrook ... were identified by analyzing citation data over the last ... work (2002-2012 and 2012-2013). The two were selected from ... , "This recognition is a great honor for Charlie ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... Sept. 7 Alba Therapeutics Corporation today,announced the ... Senior Vice,President, Clinical Development and Medical Affairs. In ... leading Alba,s clinical development strategy,and program execution through ... serve as a member of Alba,s executive management,leadership ...
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... today announced that it will deliver poster,presentations at ... its anti-cancer antibody drug candidates. At the ... September 7-8,Arius will report recent results of its ...
... 1959, Nobel Prize winner Richard Feynman presented a talk entitled ... that there was no physical reason why humans couldn,t manipulate ... of observing the new atom positions remains. How do ... the Sept. 7, 2007 issue of Science, IBM and Imago ...
Cached Biology Technology:Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 3IBM and Imago find a crucial difficulty in semiconductor device scaling 2
(Date:7/25/2014)... WASHINGTON (July 24, 2014)The link between autism and ... the puzzle of the disease, and is largely ... Foundation Autism Research Initiative (SFARI), George Washington University ... to offer truly integrative and in-depth answers to ... research. , LaMantia, professor of pharmacology and ...
(Date:7/25/2014)... MA A study published online in the ... a novel approach to preventing cervical cancer based on ... cancer after removal of a discrete population of cells ... a study that looked at squamocolumnar junction cells, or ... and have been implicated as the origins of cervical ...
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2Clearing cells to prevent cervical cancer 2Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... receive a special discretionary prize, as part of the ... The European Molecular Biology Organization (EMBO) awards the prize ... communication with the public. The additional award was made ... a single organism using all available media. , ...
... Barbara, Calif.) It,s no secret that humans are having ... animals. UC Santa Barbara,s Steven D. Gaines and fellow researcher ... world,s far-flung islands. Their research, published this month in ... sheds surprising light on the subject of extinction rates of ...
... Organization (EMBO) announced that the German evolutionary biologist Axel ... the 2008 EMBO Award for Communication in the Life ... scientist in Europe for outstanding communication with the public. ... continuous endeavour to convey complex scientific topics to the ...
Cached Biology News:EMBO recognizes German zoologist for public communication 2Study of islands reveals surprising extinction results 2Study of islands reveals surprising extinction results 3Prominent German biologist wins EMBO Communication Award 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: